Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

PURPOSE: Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior...

詳細記述

保存先:
書誌詳細
主要な著者: Choueiri, Toni K., Ross, Robert W., Jacobus, Susanna, Vaishampayan, Ulka, Yu, Evan Y., Quinn, David I., Hahn, Noah M., Hutson, Thomas E., Sonpavde, Guru, Morrissey, Stephanie C., Buckle, Geoffrey C., Kim, William Y., Petrylak, Daniel P., Ryan, Christopher W., Eisenberger, Mario A., Mortazavi, Amir, Bubley, Glenn J., Taplin, Mary-Ellen, Rosenberg, Jonathan E., Kantoff, Philip W.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2012
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4104290/
https://ncbi.nlm.nih.gov/pubmed/22184381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.7002
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料